Central neurotoxicity of immunomodulatory drugs in multiple myeloma

  • Urmeel H. Patel Penn State Hershey Cancer Institute, Hershey, PA, United States.
  • Muhammad A. Mir Penn State Hershey Cancer Institute, Hershey, PA, United States.
  • Jeffrey K. Sivik Penn State Hershey Cancer Institute, Hershey, PA, United States.
  • Divisha Raheja Penn State Hershey Cancer Institute, Hershey, PA, United States.
  • Manoj K. Pandey Penn State Hershey Cancer Institute, Hershey, PA, United States.
  • Giampaolo Talamo | gtalamo@hmc.psu.edu Penn State Hershey Cancer Institute, Hershey, PA, United States.

Abstract

Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2015-03-03
Info
Issue
Section
Case Reports
Keywords:
multiple myeloma, central neurotoxicity, immunomodulatory drugs, thalidomide, lenalidomide, pomalidomide
Statistics
  • Abstract views: 1895

  • PDF: 731
  • HTML: 191
How to Cite
Patel, U., Mir, M., Sivik, J., Raheja, D., Pandey, M., & Talamo, G. (2015). Central neurotoxicity of immunomodulatory drugs in multiple myeloma. Hematology Reports, 7(1). https://doi.org/10.4081/hr.2015.5704

Most read articles by the same author(s)